Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Bao Pharmaceuticals Co (HKSE:02659) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shanghai Bao Pharmaceuticals Co Net Margin % Related Terms
Shanghai Bao Pharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bao Pharmaceuticals Co Net Margin % Chart
Shanghai Bao Pharmaceuticals Co Annual Data
Trend
Dec23
Dec24
Dec25
Net Margin %
-2,314.47
-5,916.00
-804.18
Shanghai Bao Pharmaceuticals Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Net Margin %
0.00
-11,220.81
-4,222.37
-436.04
-2,961.46
HKSE:02659 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Shanghai Bao Pharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Bao Pharmaceuticals Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Bao Pharmaceuticals Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Bao Pharmaceuticals Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a Net Margin % of -2,961.46% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. According to the industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #732 out of 942 companies in the Biotechnology industry, placing it in the top 77.7%.
Is Shanghai Bao Pharmaceuticals Co's Net Margin % too high?
Shanghai Bao Pharmaceuticals Co's current Net Margin % is -2,961.46%. Based on the distribution chart, Shanghai Bao Pharmaceuticals Co ranks #732 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Bao Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bao Pharmaceuticals Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #732 out of 942 companies for Net Margin %. This places Shanghai Bao Pharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. Shanghai Bao Pharmaceuticals Co's current Net Margin % is -2,961.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bao Pharmaceuticals Co stock overvalued right now?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a current Net Margin % of -2,961.46%. The current Net Margin % is -2,961.46%. Shanghai Bao Pharmaceuticals Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shanghai Bao Pharmaceuticals Co (HKSE:02659), the current Net Margin % is -2,961.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology company with an approved product and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. The company has proprietary technology platforms, supported by its chassis cell engineering technology, that combine drug design and bioprocessing capabilities. It has production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes. The group has only one reportable operating segment, which is the research, development, and commercialisation of pharmaceutical products.
9GF Score
Get the complete analysis for HKSE:02659
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02659 has been successfully added to your 
